Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Healthy volunteers help measure how well cizutamig absorbs under the skin

NCT ID NCT07236411

Knowledge-focused Sponsor: Candid Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study in 24 healthy adults aims to measure how much of the experimental drug cizutamig reaches the bloodstream when given as a shot under the skin compared to directly into a vein. Participants will receive either the drug or a placebo and be monitored for side effects and drug levels. The study does not aim to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cizutamig

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

24 people

The number who actually took part.

Started

Dec 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18-65 years of age 2. Body mass index 18-30 kg/m2 and weight 55-100 kg 3. Individuals in good health 4. Meets vaccination requirements as defined by the protocol 5. Agree to abstain from consumption of alcohol within 48-hrs of study visits 6. Agree to the use of highly effective contraception as defined by the protocol Exclusion Criteria: 1. Active Infection 2. Inadequate clinical laboratory parameters at Screening 3. Receipt of or inability to discontinue any excluded therapies 4. Individuals who will decline blood products 5. Individuals with immediate household contacts with young children (eg, ≤ 6 years old) or immunocompromised persons 6. History of drug or alcohol abuse within last 12 months 7. Individuals who are hypersensitive to intravenous immunoglobulin (IVIg) 8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug 9. Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period (from Screening to the individual's last visit) 10. Blood donation or significant blood loss within 30 days prior to screening 11. Individuals considered to be part of a vulnerable population (eg, incarceration) 12. Individuals that in the opinion of the Investigator, are not suitable for participation in the trial 13. Inability to comply with protocol-mandated requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants study are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants study

Contacts and locations

Locations

  • Nucleus Network

    Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.